PMID- 32093874
OWN - NLM
STAT- MEDLINE
DCOM- 20201015
LR  - 20201015
IS  - 1879-114X (Electronic)
IS  - 0149-2918 (Linking)
VI  - 42
IP  - 3
DP  - 2020 Mar
TI  - Associations Between Polymorphisms of Endothelial Nitric Oxide Synthase, Matrix 
      Metalloproteinase 3, Angiotensinogen, and Angiotensin II Type 1 Receptor and Risk 
      of Restenosis After Percutaneous Coronary Intervention: A Meta-analysis.
PG  - 458-474
LID - S0149-2918(20)30054-0 [pii]
LID - 10.1016/j.clinthera.2020.01.018 [doi]
AB  - PURPOSE: Previous studies have reported controversial results regarding the risk 
      of restenosis with polymorphisms of endothelial nitric oxide synthase (eNOS), 
      matrix metalloproteinase 3 (MMP-3), angiotensinogen (AGT), and angiotensin II 
      type 1 receptor (AT1R) after percutaneous coronary intervention (PCI). This study 
      aimed to summarize the association between these polymorphisms and risk of 
      restenosis after PCI. METHODS: We searched the electronic databases of PubMed, 
      Embase, Cochrane's Library, and ClinicalTrials.gov for studies on the association 
      of eNOS, MMP-3, AGT, and AT1R polymorphisms with restenosis. FINDINGS: A total of 
      17 studies (7781 patients) were analyzed, including 5 studies on eNOS G298A 
      (n = 912), 5 studies on MMP3 5A/6A (n = 4519), 6 studies on AGT M235T (n = 1801), 
      and 7 studies on AT1R A1166C (n = 2477). For the G298A variant of the eNOS gene, 
      the allele odds ratio (OR) was 1.685 (95% CI, 1.269-2.338; P < 0.001), the 
      heterozygote OR was 2.144 (95% CI, 1.490-3.085; P < 0.001), the dominant OR was 
      2.078 (95% CI, 1.462-2.954; P < 0.001), and the overdominant OR was 0.496 (95% 
      CI, 0.348-0.706; P < 0.001). For the 5A/6A variant of the MMP3 gene, the 
      heterozygote OR was 0.839 (95% CI, 0.722-0.975; P = 0.022), the dominant OR was 
      0.846 (95% CI, 0.733-0.976; P = 0.022), and the overdominant OR was 1.141 (95% 
      CI, 1.001-1.301; P = 0.049). For the M235T variant of the AGT gene, the 
      heterozygote OR was 1.594 (95% CI, 1.179-2.155; P = 0.002), the dominant OR was 
      1.437 (95% CI, 1.077-1.918; P = 0.014), and the overdominant OR was 0.694 (95% 
      CI, 0.555-0.869; P = 0.001). Positive results were observed in the AT1R gene 
      A1166C polymorphism under 3 models (homozygote OR = 2.009; 95% CI, 1.433-2.816; 
      P < 0.001; recessive OR 1.874; 95% CI, 1.353-2.595; P < 0.001; and dominant 
      OR = 1.350; 95% CI, 1.105-1.649; P = 0.003). IMPLICATIONS: The G298A variant of 
      eNOS, the 5A/6A variant of MMP3, the M235T variant of AGT, and the A1166C variant 
      of A1TR may increase the risk of restenosis after PCI.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Zhou, Shuang
AU  - Zhou S
AD  - Department of Pharmacy, Peking University First Hospital, Beijing, People's 
      Republic of China; Department of Pharmacy Administration and Clinical Pharmacy, 
      School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic 
      of China.
FAU - Mu, Guangyan
AU  - Mu G
AD  - Department of Pharmacy, Peking University First Hospital, Beijing, People's 
      Republic of China; Department of Pharmacy Administration and Clinical Pharmacy, 
      School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic 
      of China.
FAU - Wei, Shaopeng
AU  - Wei S
AD  - Department of Pharmacy, Peking University First Hospital, Beijing, People's 
      Republic of China.
FAU - Liu, Zhiyan
AU  - Liu Z
AD  - Department of Pharmacy, Peking University First Hospital, Beijing, People's 
      Republic of China; Department of Pharmacy Administration and Clinical Pharmacy, 
      School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic 
      of China.
FAU - Wang, Zhe
AU  - Wang Z
AD  - Department of Pharmacy, Peking University First Hospital, Beijing, People's 
      Republic of China.
FAU - Xiang, Qian
AU  - Xiang Q
AD  - Department of Pharmacy, Peking University First Hospital, Beijing, People's 
      Republic of China.
FAU - Cui, Yimin
AU  - Cui Y
AD  - Department of Pharmacy, Peking University First Hospital, Beijing, People's 
      Republic of China; Department of Pharmacy Administration and Clinical Pharmacy, 
      School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic 
      of China. Electronic address: cui.pharm@pkufh.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200221
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (AGT protein, human)
RN  - 0 (Receptor, Angiotensin, Type 1)
RN  - 11002-13-4 (Angiotensinogen)
RN  - EC 1.14.13.39 (NOS3 protein, human)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type III)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Angiotensinogen/*genetics
MH  - Coronary Stenosis/epidemiology/genetics/surgery
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Matrix Metalloproteinase 3/*genetics
MH  - Nitric Oxide Synthase Type III/*genetics
MH  - *Percutaneous Coronary Intervention/adverse effects/statistics & numerical data
MH  - Polymorphism, Single Nucleotide/genetics
MH  - Postoperative Complications/epidemiology/genetics/surgery
MH  - Receptor, Angiotensin, Type 1/*genetics
MH  - Recurrence
OTO - NOTNLM
OT  - AGT
OT  - AT1R
OT  - MMP-3
OT  - eNOS
OT  - polymorphisms
OT  - risk of restenosis
COIS- Disclosures The authors have indicated that they have no conflicts of interest 
      regarding the content of this article.
EDAT- 2020/02/26 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/02/26 06:00
PHST- 2019/11/07 00:00 [received]
PHST- 2020/01/22 00:00 [revised]
PHST- 2020/01/26 00:00 [accepted]
PHST- 2020/02/26 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/02/26 06:00 [entrez]
AID - S0149-2918(20)30054-0 [pii]
AID - 10.1016/j.clinthera.2020.01.018 [doi]
PST - ppublish
SO  - Clin Ther. 2020 Mar;42(3):458-474. doi: 10.1016/j.clinthera.2020.01.018. Epub 
      2020 Feb 21.